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ABSTRACT
Introduction During the last trimester of pregnancy, 
the fetal brain undergoes a rapid growth spurt 
and accumulates essential nutrients including 
docosahexaenoic acid (DHA). This takes place ex- utero for 
infants born <29 weeks’ gestation, without the in- utero 
provisions of DHA. Infants born <29 weeks’ are more likely 
to experience behavioural and emotional difficulties than 
their term- born counterparts. It has been hypothesised 
that supplementing preterm infants with dietary DHA 
may alleviate insufficiency and subsequently prevent or 
minimise behavioural problems. This protocol describes 
a follow- up of infants born <29 weeks gestation who 
were enrolled in a randomised controlled trial (RCT) of 
DHA supplementation. We aim to determine whether DHA 
supplementation improves the behaviour, and general 
health of these infants.
Methods and analysis Infants born <29 weeks’ 
gestation were enrolled in a multicentre blinded RCT of 
enteral DHA supplementation. Infants were randomised to 
receive an enteral emulsion that provided 60 mg/kg/day 
of DHA or a control emulsion commenced within the first 
3 days of enteral feeding, until 36 weeks’ postmenstrual 
age or discharge home, whichever occurred first. Families 
of surviving children (excluding those who withdrew 
from the study) from the Australian sites (up to 955) will 
be invited to complete a survey. The survey will include 
questions regarding child behavioural and emotional 
functioning, executive functioning, respiratory health and 
general health. We hypothesise that the DHA intervention 
will have a benefit on the primary outcome, parent- rated 
behaviour and emotional status as measured using the 
Total Difficulties score of the Strengths and Difficulties 
Questionnaire. Detecting a 2- point difference between 
groups (small effect size of 0.25 SD) with 90% power will 
require follow- up of 676 participants.
Ethics and dissemination The Women’s and Children 
Health Network Human Research Ethics Committee 
reviewed and approved the study (HREC/16/WCHN/184). 
Results will be disseminated in peer- reviewed publications 
and conference presentations.
Trial registration number ACTRN12612000503820.
INTRODUCTION
Docosahexaenoic acid (DHA, 22:6 n-3) is an 
omega-3 long- chain polyunsaturated fatty 
acid (n-3 LCPUFA) that is crucial for the 
developing brain. DHA is present in all cell 
membranes as a structural component of the 
phospholipid bilayer with an integral role 
in membrane fluidity.1 It is concentrated in 
the brain2 3 where it is known to be involved 
in neurogenesis, signal transduction and 
neurotransmission.4 In the last trimester of 
a normal pregnancy, it is estimated that the 
Strengths and limitations of this study
 ► This study will be the largest follow- up of a ran-
domised controlled trial of enteral docosahexaenoic 
acid (DHA) supplementation for infants born preterm.
 ► This follow- up will determine the effect of enteral 
DHA supplementation for infants born <29 weeks’ 
gestation on child behaviour and emotional state.
 ► This follow- up study will assess a range of gen-
eral health outcomes for infants born <29 weeks’ 
gestation.
 ► Loss to follow- up 5 years after enrolment into the 
trial may contribute to risk of bias.
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fetus acquires ~70 mg of n-3 LCPUFA per day, largely as 
DHA5 and this peak period of neural tissue DHA accumu-
lation coincides with the fetal brain growth spurt.6
Preterm birth can slow the fetal brain growth spurt as 
well as interrupts the usual placental supply of nutrients 
such as DHA. Infants born preterm typically have lower 
neural tissue DHA levels than term- born infants.6 7 They 
are more likely to experience poor neurobehavioural 
outcomes compared with infants born at term.8–19 The risk 
of suboptimal development increases as gestational age at 
birth decreases,9 13 20–22 and among those born <28 weeks’ 
gestational age, 52% of survivors will have some neurobe-
havioural disability.23 Behavioural problems,9 11 13–17 19 24–26 
such as attention difficulties,9 18 27 28 and anxiety,26 27 29 30 as 
well as executive functioning difficulties (struggling with 
skills essential for undertaking goal- oriented behaviours 
including inhibitory control)10 30 31 are common issues for 
children born preterm when compared with their term- 
born counterparts.
Insufficient dietary DHA in the neonatal period for 
preterm infants may be a modifiable contributing factor 
to the increased rate of poor neurobehavioural outcomes. 
Randomised controlled trials (RCTs) of infants born 
preterm have compared treatment with supplemental 
DHA with control to assess the impact on child develop-
ment. These have produced inconclusive results.32–34 The 
most promising evidence comes from two trials that supple-
mented preterm infants with a dose equivalent to in- utero 
accretion of DHA (60 mg/kg/day) compared with the 
standard dose of DHA (20 mg/kg/day present in breast-
milk and in preterm infant formula).35 36 Study authors 
reported benefits of higher doses of DHA supplementation 
in infants born <1500 g on problem solving35 and atten-
tion37 and, in infants born <1250 g a reduction in the prev-
alence of cognitive delay.36 Follow- up assessments at 7 years 
in one of these trials revealed an unexpected potentially 
adverse interaction effect with DHA where a few instances 
of parent- rated behaviour and executive functioning were 
worse in girls who received extra DHA compared with girls 
who received the standard dose of DHA.38 39 However, these 
findings were based on secondary analyses and hence were 
insufficient to change clinical practice.
In N−3 Fatty Acids for Improvement in Respiratory 
Outcomes (N3RO), the largest trial to date, 1273 infants 
born <29 weeks’ gestation were randomised to receive 
oral supplementation of DHA (60 mg/kg/day) or control 
from within the 3 days of commencing enteral feeds until 
36 weeks’ postmenstrual age or discharge home, which-
ever occurred first.40 41 DHA provided no benefit and may 
have increased the risk of bronchopulmonary dysplasia 
(the primary outcome).41 A similar recent study also 
showed an increased risk of bronchopulmonary dysplasia 
in infants born <29 weeks’, although the trial was ceased 
early after interim analyses suggested poorer outcomes in 
the DHA group.42 Given these recent findings we can no 
longer assume safety. Equally the potential neurobehav-
ioral benefit or harm has never been adequately demon-
strated in extremely preterm infants.
The N3RO trial recruited infants at high risk of adverse 
neurobehavioural outcomes23 and offers a unique oppor-
tunity to determine whether DHA supplementation 
improves neurobehavioural outcomes.
We aim to follow- up the N3RO trial children to eval-
uate the effect of DHA supplementation in infants born 
<29 weeks’ gestation on behavioural, emotional and 
executive functioning at early school age. We hypothe-
sise that infants <29 weeks’ gestation provided with oral 
DHA supplements in the first months of life in amounts 
resembling transplacental acquisition will have fewer 
behavioural, emotional and executive function prob-
lems at 5 years’ corrected age compared with infants who 
received the control intervention.
METHODS
The N3RO trial
Infants were eligible for N3RO if they were born <29 
weeks’ gestation, were able to be recruited within 3 days 
of their first enteral feed and had a parent or guardian 
capable of providing written informed consent. Infants 
were ineligible if they were participating in another fatty 
acid intervention trial, if they had a major congenital 
or chromosomal abnormality, if a breastfeeding mother 
was taking DHA containing supplements of more than 
250 mg/day, or if they were receiving intravenous lipids 
containing fish oil.41 A total of 1273 infants were enrolled 
into the N3RO trial from 13 centres in Australia, New 
Zealand and Singapore between 2012 and 2015.
On enrolment, infants were randomised to receive 
an enteral emulsion that provided either 60 mg of DHA 
per kg of body weight per day (intervention group), or a 
control emulsion without DHA (control group).41 Infants 
received the study emulsion from enrolment to either 
discharge home or 36 weeks’ postmenstrual age, which-
ever occurred first. Intervention and control emulsions 
were identical in viscosity, colour and packaging to ensure 
blinding of families, clinical staff and study personnel.41 
Infants were randomised through a secure web- based 
server using an independently generated randomisation 
schedule stratified for gestational age at birth <27 weeks 
or 27–28 weeks, sex and centre; infants from multiple 
births were randomised individually.
Follow-up study procedure
This is a follow- up study of infants enrolled in the 
N3RO trial from the Australian centres who had not 
died or withdrawn from the trial. This follow- up was 
not specified in the original N3RO trial protocol, 
however at enrolment into the N3RO trial families gave 
consent to be contacted in the future for follow- up 
studies. Hospital records from the enrolment centres 
will be checked to confirm children are not deceased 
prior to contacting families. Caregivers of surviving 
N3RO trial infants will be invited to complete an online 
survey when their child reaches 5 years’ corrected 
age. Study personnel are blinded to randomisation. 
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Families had the opportunity to request knowledge of 
their group allocation after completion of the N3RO 
trial primary outcome analyses. The number of families 
who requested to be unblinded overall will be reported, 
along with the number of families who were unblinded 
and participated in the follow- up.
The survey comprises multiple parent- rated measures 
of child behaviour, behavioural manifestations of exec-
utive functioning, health- related quality of life, symp-
toms of asthma and allergy, child general health, family 
functioning, parenting style, current dietary intake of 
food and supplement sources of DHA and the quality of 
the social and emotional support available in the home 
environment. The entire survey takes on average 40 min 
(between 20 min to 60 min) to complete. The survey 
can be completed online (via a personalised link sent 
through email or text message), or if caregivers prefer, a 
posted hard- copy or via interview over the telephone with 
study staff.
Caregivers of surviving, eligible N3RO trial children 
will be emailed a letter of invitation to the follow- up study 
2 months before their child reaches 5 years’ corrected 
age, followed by a telephone call to answer any ques-
tions, clarify willingness to participate and ascertain 
mode of preferred survey completion. Contact details 
provided at enrolment in the N3RO trial, and updated 
details provided during yearly mail- outs will be used to 
contact eligible families. Age is corrected for prematu-
rity to avoid a known bias in standardised test scores for 
children born preterm.43 Families will be reimbursed 
with an $A40 gift voucher for completing the survey. 
Assessments for this follow- up study commenced 29 
August 2018 and are expected to be completed by June 
2021.
Participants
Children are eligible and will be invited to participate in 
this follow- up if they were enrolled at any of the Austra-
lian sites; the Flinders Medical Centre (South Australia), 
John Hunter Hospital (New South Wales), King Edward 
Memorial Hospital (Western Australia), Liverpool 
Hospital (New South Wales), Mater Mothers’ Hospital 
(Queensland), Mercy Hospital for Women (Victoria), 
Monash Children’s Hospital (Victoria), Royal Hospital for 
Women (New South Wales), The Royal Women’s Hospital 
(Victoria) and the Women’s and Children’s Hospital 
(South Australia). Families will not be approached if their 
child was withdrawn from the N3RO trial or if N3RO 
study staff are notified that the child has died.
Outcomes and measures
For this study, all outcome measures are derived from 
questionnaires (see table 1) to be completed by caregivers 
using the Research Electronic Data Capture (REDCap) 
software platform.44 45 Surveys completed in hard copy or 
via interview over the phone will be entered into REDCap.
Primary outcome
The primary outcome is behavioural functioning as 
assessed by the Total Difficulties Score of the Strengths 
and Difficulties Questionnaire (SDQ). The SDQ is a 
parent- completed rating of symptoms of behavioural 
problems.46 The parent- completed version of the SDQ 
for children age 4–10 years will be used. Caregivers are 
asked to rate their child’s behaviour and emotional 
state in comparison to other children of the same age. 
The SDQ has good test–retest stability (r=0.62, after 4–6 
months) and internal consistency for the Total Difficul-
ties scale (α=0.82).47 Despite being a screening test, the 
parent- rated version of the SDQ Total Difficulties scale 
has demonstrated good sensitivity and positive predictive 
validity for psychiatric diagnoses in children.47
Secondary Outcomes
Other SDQ scales
The SDQ contains 25 items, split evenly into five scale 
scores; Emotional Symptoms, Conduct Problems, Hyper-
activity/Inattention, Peer Relationship Problems and 
Prosocial Behaviour.46 Higher scores for all scales and 
composites (excepting Prosocial Behaviour), indicate 
more perceived symptoms of a behavioural problem. 
Although scores on the SDQ are not standardised, they 
will be categorised as normal (<14) or abnormal/indica-
tive of dysfunction (14 or higher) according to Australian 
norms48 49 and compared between the groups, in addition 
to comparing mean scores.
Behaviour Rating Inventory of Executive Functioning-Preschool 
edition
The parent version of the Behaviour Rating Inventory of 
Executive Functioning- Preschool edition (BRIEF- P) will 
be administered to assess behavioural manifestations of 
young children’s (two to 2–5 years) executive functions in 
everyday settings.50 The BRIEF- P is an important addition 
to formal, performance- based assessment of executive 
functioning as some elements of executive dysfunction 
are only obvious in everyday situations, such as the home. 
The BRIEF- P has five scales (Inhibit Scale, Emotional 
Control Scale, Shift Scale, Working Memory Scale and 
Plan/Organise Scale) that make up three indices (Inhib-
itory Self Control Index, Flexibility Index and Emergent 
Metacognition Index) and an overall Global Executive 
Composite score.
Scores are age- standardised to a mean of 50, SD=10, 
and higher scores indicate more symptoms of executive 
dysfunction.50 Scaled scores at or above 65 are catego-
rised as dysfunctional and scores below 65 are catego-
rised as normal and will be compared between groups, 
as will mean scores for each domain. Scores will be age- 
standardised according to corrected age (corrected for 
preterm birth) at the time of survey completion. For 
children who are older than 6 years’ corrected age at the 
time of the survey completion, caregivers will be asked to 
complete the BRIEF2 (BRIEF, Second Edition, for chil-
dren aged 6–18 years).51 The BRIEF2 has slightly different 
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(age- appropriate) subscales and indices to the BRIEF- P 
but has the same overall standardised Global Executive 
Composite score.
General health
Child’s health status will be compared between the groups 
in terms of whether they have been diagnosed (yes/no) 
with a cognitive, behavioural or emotional disorder, 
blindness, hearing- loss or deafness, physical disability, 
autism spectrum disorder or other medical conditions by 
a health professional, and whether the child has received 
services of a physiotherapist, speech therapist, occu-
pational therapist, psychologist, behavioural therapist, 
psychiatrist or other allied health professional. Caregivers 
will be asked about any surgical procedures that the child 
has undergone since discharge from hospital, as well as 
any respiratory- related hospital admissions.
International Study of Asthma and Allergies in Childhood
The International Study of Asthma and Allergies in Child-
hood (ISAAC) questionnaire is a brief parent- completed 
measure of the frequency and severity of allergic disease, 
including respiratory symptoms in the previous 12 
months.52 As the primary outcome of the original N3RO 
trial was bronchopulmonary dysplasia,41 the ISAAC ques-
tionnaire will be important for providing an indication of 
any effect of DHA on respiratory health.
Paediatric Quality of Life Inventory
The Paediatric Quality of Life Inventory (PedsQL) is 
a parent- rated measure of general well- being and the 
health- related quality of life in healthy children, and in 
children with acute or chronic health conditions. A total 
of 23 items assess Physical Functioning, Emotional Func-
tioning, Social Functioning and School Functioning and 
provide mean scores for each domain as well as an overall 
score to be compared between groups.53
Background information and sample characteristics
There will be a descriptive comparison of background 
characteristics and the following post- randomisation 
characteristics. Socio- demographic data were collected 
at enrolment into the N3RO trial (such as parental age, 
education, employment) through interview with the care-
giver. Clinical characteristics of infants from baseline to 
discharge home, or 40 weeks’ postmenstrual age (which-
ever occurred first) were collected from medical records 
as part of the N3RO trial.
As part of this protocol, current details about the 
child’s home and medical background will be recorded. 
Caregivers will be asked about the child’s family structure, 
whether English is the primary language spoken at home, 
whether the child attends or attended pre- school or full- 
time primary school. Caregivers will also be asked about 
whether the child has consumed dietary DHA from DHA 
containing supplements (on at least 3 days per week) and 
the number of fish meals (one meal=60–80 g of fish) in 
the last month.
The home environment
Indicators of the quality of the home environment will be 
captured and descriptively compared with to check for 
balance between groups as stimulation within the home, 
parenting and family functioning all have an influence 
on child development and behaviour.54–57 The family 
home environment will be assessed through three parent- 
completed questionnaires. Families with more than one 
child in the follow- up study will only need to complete 
these questionnaires once. The 12- item General Family 
Functioning scale (considered the short Family Assess-
ment Device) of the Family Assessment Device will be 
administered to measure problem solving by the family 
as a whole.58 The Parental Involvement in Developmental 
Advance subscale of the StimQ, will be used to assess 
parental involvement in child learning activities.59
The Parenting Scale captures parenting style in different 
scenarios to measure dysfunctional parenting when disci-
pline is needed.60 The 30- item questionnaire assesses 
the probability of using different disciplinary strategies. 
The scale generates an overall score as well as scales for 
Laxness (permissive or inconsistent style), Over- reactivity 
(emotional, irritable, harsh or authoritarian style) and 
Hostility (use of verbal or physical force).60
Sample size
A total of 1028 children were randomised in the 10 
Australian sites in the N3RO trial. Excluding 66 deaths 
and 7 withdrawals from the original N3RO trial, 955 chil-
dren are potentially available for follow- up. A sample size 
of 338 children per group (676 total, approximately 70% 
of those potentially available) will provide 90% power, 
two- tailed alpha 0.05, to detect a 0.25 SD mean difference 
(small effect size) between groups in the Total Difficul-
ties score of the SDQ. Based on our earlier follow- up of 
7- year- old children born <33 weeks’ gestation enrolled in 
a DHA RCT,38 we expect an effect size of 0.25 SD to corre-
spond to a mean difference in the Total Difficulties score 
of approximately 2 points.
No adjustment to the sample size is needed for clus-
tering due to multiple births, since children were 
randomised individually in N3RO and the design effect 
for continuous outcomes is one in this case.61 The sample 
size calculation was performed with Stata V.15 software 
(StataCorp LP) assuming a linear regression model 
for analysis (equivalently a two- sample t- test with equal 
variances).
Statistical analysis and data management
All analyses will be undertaken on an intention- to- treat 
basis for all surviving children from eligible centres 
according to a prespecified statistical analysis plan 
approved by the N3RO trial Steering Committee. All data 
will be identified through the study randomisation iden-
tification numbers assigned at enrolment into the N3RO 
trial. Identification numbers are associated with a code to 
indicate group allocation (available to the trial statistician 
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only) so that data can be analysed blinded to treatment 
group.
The following data will be descriptively compared 
between the groups to determine comparability of 
sample characteristics; baseline characteristics (such as 
infant sex and maternal education), characteristics and 
5 years’ corrected age (such as family structure and atten-
dance at school) and the home environment (such as the 
Family Assessment Device, the StimQ and the Parenting 
Scale scores). Outcomes to be compared between rando-
misation groups are all outcomes from the SDQ, BRIEF- P, 
ISAAC and the PedsQL, as well as the general health of 
the children at the time of the follow- up (such as pres-
ence of neurological diagnoses).
Outcomes of intervention and control group children 
will be compared using generalised linear models, with 
generalised estimated equations used to account for 
clustering due to multiple births within the same family. 
Continuous and binary outcomes will be analysed using 
linear and log binomial models, respectively, with adjust-
ment for variables used to stratify the randomisation: sex, 
centre enrolled and gestational age (<27 completed weeks 
or 27–28 weeks). For all outcomes, preplanned subgroup 
analyses will be performed to test for evidence of effect 
modification by sex and gestational age (less than 27 
weeks, 27 to less than 29 weeks). Effect modification will 
be assessed by including an interaction term between the 
subgroup variable and treatment group into the regres-
sion model for each outcome. Estimates of the treatment 
effect within each subgroup will be reported, indepen-
dent of the degree of evidence for effect modification, 
since these treatment effects are a priori of interest. 
No adjustment will be made for multiple preplanned 
comparisons, as the single primary outcome of interest is 
the SDQ Total Difficulties score and all other analyses will 
be hypothesis- generating secondary outcomes.
Missing outcome data will be addressed using multiple 
imputation, with imputation performed separately by 
treatment group using fully conditional specification.62 
Imputed data sets will include all surviving children from 
the 10 included centres.
Data will be entered into a REDCap database, which 
uses a MySQL database via a secure web interface with 
data checks used during data entry to ensure data quality. 
Data from the survey will be stored on secure servers 
within the South Australian Health and Medical Research 
Institute for a minimum of 30 years. Data will be acces-
sible only by study staff and investigators.
Ethical considerations and dissemination of results
This study will be carried out in accordance with the 
Australian National Statement on Ethical Conduct in 
Research Involving Humans,63 which builds on the ethical 
codes of the Declaration of Helsinki and the Principles of 
International Conference on Harmonisation64 Good Clin-
ical Practice (as adopted in Australia).65 All procedures 
and study materials have been reviewed and approved 
by the Women’s and Children’s Health Network Human 
Research Ethics Committee (HREC/16/WCHN/184), 
as well as the Research Governance Offices at each site. 
The N3RO Trial and this follow- up are registered on the 
Australia and New Zealand Clinical Trial Registry.
Caregivers will be provided with detailed written 
information about the study and will provide informed 
consent for their child’s involvement in the form of either 
e- consent built into the survey, or a hard- copy written 
form. Data collected will be treated with confidence and 
caregivers will be free to withdraw their children from the 
study at any time without prejudice.
The results of this follow- up study will be presented at 
academic conferences and published in peer- reviewed 
journals. No participants will be identified in the dissemi-
nation of study results.
Access to data
Individual participant data, including data dictionaries, 
may be shared after de- identification on reasonable 
request. Proposals to access the data must be scientifi-
cally and methodologically sound and must be reviewed 
and approved by the N3RO trial Steering Committee and 
the Women’s and Children’s Human Research Ethics 
Committee. To gain access, data requestors will need 
to sign a data access agreement. Proposals should be 
directed to Jacqueline Gould through email ( Jacqueline. 
gould@ sahmri. com).
Patient and public involvement
Neither caregivers or families of patients nor the public 
were directly involved in the development of the research 
question or design of this follow- up study. However, our 
primary outcome of behaviour is based on reported 
concerns over long- term developmental concerns from 
parents of preterm infants.66
A Community Board, comprising parents (including 
parents of a child born preterm) as well as clinicians and 
researchers specialising in paediatrics will be consulted 
for the dissemination of the study findings to partici-
pants, including reviewing the study results and format 
of dissemination.
DISCUSSION
Approximately 15 million infants are born preterm world-
wide each year,67 with increasing survival into childhood of 
infants born as early as 23 weeks’ gestation. However, the 
risk of long- term behavioural and emotional difficulties in 
survivors remains high68 69 and there is evidence that the 
prevalence of behavioural problems is increasing.16 70–74
The N3RO trial, along with another trial in breastfed 
infants, showed no benefit of the DHA intervention 
on bronchopulmonary dysplasia, but the effect of 
DHA on childhood neurobehavioural outcomes in 
this specific population–infants born <29 weeks’ gesta-
tion–is unknown.41 42 A preliminary follow- up of a small 
subgroup (n<100) of the N3RO children in infancy75 
detected no effect of the DHA intervention on their 
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executive function, visual attention or on cognition, 
motor or language abilities76 although the sample was 
under- powered to detect an effect on cognition, motor or 
language development.75 76 Further follow- up of a larger 
sample of the N3RO trial children is needed to determine 
the effectiveness of the DHA intervention on behavioural 
outcomes.77
This study is the largest follow- up study after a DHA 
intervention in preterm infants, and is the first early 
DHA intervention study with behaviour as a main 
outcome.32 77–82 In addition to behavioural and emotional 
status, we will assess the effect of the DHA intervention 
on the manifestations of executive functioning skills in 
everyday behaviour as well as child respiratory health and 
general health and well- being.
Among all preterm infants, the <29 week infants such 
as those recruited to the N3RO trial were at risk of 
prolonged exposure to low DHA exposure and are at 
particularly high- risk for problematic neurobehavioural 
development. Hence, they represent an ideal sample 
for evaluating whether enteral DHA supplementation 
improves neurobehavioural development.77 83 A possible 
limitation of the study design is that a subset of the 1273 
children from the original trial from the 10 Australian 
sites, of the 13 international enrolling centres, will be 
invited to participate in this survey, possibly introducing 
bias due to differences in populations and clinical care 
between enrolling centres, although there is no evidence 
of systematic differences in the intervention according 
to site or country. Loss to follow- up 5 years after the trial 
enrolment may introduce attrition bias. Parents were 
able to request their group allocation after analysis of 
the primary outcome, and although few families were 
unblinded, knowledge of the intervention received may 
introduce bias.
The result of this follow- up will contribute to the eval-
uation of the risks and benefits of providing preterm 
infants with high- dose DHA during the neonatal period. 
Any potential benefit detected in the course of this 5- year 
follow- up study would need to be balanced against the 
possible short- term adverse effect on the risk of broncho-
pulmonary dysplasia.
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